These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 24726286

  • 1. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
    Chiorean EG, Schneider BP, Akisik FM, Perkins SM, Anderson S, Johnson CS, DeWitt J, Helft P, Clark R, Johnston EL, Spittler AJ, Deluca J, Bu G, Shahda S, Loehrer PJ, Sandrasegaran K, Cardenes HR.
    Int J Radiat Oncol Biol Phys; 2014 Jun 01; 89(2):284-91. PubMed ID: 24726286
    [Abstract] [Full Text] [Related]

  • 2. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN, Olsen JR, Lee AY, Yano M, Menias CO, Khwaja S, Wang-Gillam A, Strasberg SM, Hawkins WG, Linehan DC, Myerson RJ, Parikh PJ.
    Am J Clin Oncol; 2016 Feb 01; 39(1):1-7. PubMed ID: 26132367
    [Abstract] [Full Text] [Related]

  • 3. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
    Esnaola NF, Chaudhary UB, O'Brien P, Garrett-Mayer E, Camp ER, Thomas MB, Cole DJ, Montero AJ, Hoffman BJ, Romagnuolo J, Orwat KP, Marshall DT.
    Int J Radiat Oncol Biol Phys; 2014 Mar 15; 88(4):837-44. PubMed ID: 24606850
    [Abstract] [Full Text] [Related]

  • 4. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH, Zhou SQ, Yang JY, Du W, Liang G, Lei Y, Luo F.
    World J Gastroenterol; 2014 Oct 14; 20(38):13987-92. PubMed ID: 25320537
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs FT, Ebert MP, Distelrath A, Geissler M, Trojan J, Schütz M, Berie L, Sauvigny C, Lammert F, Lohse A, Dollinger MM, Lindig U, Duerr EM, Lubomierski N, Zimmermann S, Wachtlin D, Kaiser AK, Schadmand-Fischer S, Galle PR, Woerns M, Working Group of Internal Oncology.
    Eur J Cancer; 2014 Dec 14; 50(18):3125-35. PubMed ID: 25446376
    [Abstract] [Full Text] [Related]

  • 9. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
    Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, Regge D, Gabriele P, Capussotti L, Aglietta M.
    Cancer; 2013 Jan 15; 119(2):277-84. PubMed ID: 22778019
    [Abstract] [Full Text] [Related]

  • 10. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.
    Hunter KU, Feng FY, Griffith KA, Francis IR, Lawrence TS, Desai S, Murphy JD, Zalupski MM, Ben-Josef E.
    Int J Radiat Oncol Biol Phys; 2012 Jul 01; 83(3):921-6. PubMed ID: 22208966
    [Abstract] [Full Text] [Related]

  • 11. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
    Mayahara H, Ito Y, Morizane C, Ueno H, Okusaka T, Kondo S, Murakami N, Morota M, Sumi M, Itami J.
    BMC Cancer; 2012 Dec 20; 12():609. PubMed ID: 23256481
    [Abstract] [Full Text] [Related]

  • 12. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.
    Shaikh T, Wang LS, Egleston B, Burki M, Hoffman JP, Cohen SJ, Meyer JE.
    Am J Clin Oncol; 2018 Jan 20; 41(1):59-64. PubMed ID: 26325492
    [Abstract] [Full Text] [Related]

  • 13. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
    Kim R, Prithviraj GK, Shridhar R, Hoffe SE, Jiang K, Zhao X, Chen DT, Almhanna K, Strosberg J, Campos T, Shibata D.
    Radiother Oncol; 2016 Feb 20; 118(2):382-6. PubMed ID: 26861740
    [Abstract] [Full Text] [Related]

  • 14. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
    Kim JS, Lim JH, Kim JH, Im SA, Chie EK, Hwang JH, Kim TY, Bang YJ, Ha SW, Yoon YB.
    Cancer Chemother Pharmacol; 2012 Sep 20; 70(3):381-9. PubMed ID: 22806305
    [Abstract] [Full Text] [Related]

  • 15. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
    Den RB, Kamrava M, Sheng Z, Werner-Wasik M, Dougherty E, Marinucchi M, Lawrence YR, Hegarty S, Hyslop T, Andrews DW, Glass J, Friedman DP, Green MR, Camphausen K, Dicker AP.
    Int J Radiat Oncol Biol Phys; 2013 Feb 01; 85(2):321-8. PubMed ID: 22687197
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
    Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA.
    Clin Cancer Res; 2013 May 15; 19(10):2745-54. PubMed ID: 23444220
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
    Sudo K, Hara R, Nakamura K, Kita E, Tsujimoto A, Yamaguchi T.
    Cancer Chemother Pharmacol; 2017 Jul 15; 80(1):195-202. PubMed ID: 28597040
    [Abstract] [Full Text] [Related]

  • 18. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
    Gurka MK, Collins SP, Slack R, Tse G, Charabaty A, Ley L, Berzcel L, Lei S, Suy S, Haddad N, Jha R, Johnson CD, Jackson P, Marshall JL, Pishvaian MJ.
    Radiat Oncol; 2013 Mar 01; 8():44. PubMed ID: 23452509
    [Abstract] [Full Text] [Related]

  • 19. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
    Martenson JA, Vigliotti AP, Pitot HC, Geeraerts LH, Sargent DJ, Haddock MG, Ghosh C, Keppen MD, Fitch TR, Goldberg RM.
    Int J Radiat Oncol Biol Phys; 2003 Apr 01; 55(5):1305-10. PubMed ID: 12654442
    [Abstract] [Full Text] [Related]

  • 20. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
    Girard N, Mornex F, Bossard N, Ychou M, Chauffert B, Wautot V.
    Int J Radiat Oncol Biol Phys; 2010 Aug 01; 77(5):1426-32. PubMed ID: 20056351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.